Apolipoprotein A-IV (ApoA-IV), a glycoprotein synthesized predominantly in the small intestine during fat absorption, is a structural component of HDL and chylomicrons. Its four-helix bundle architecture facilitates lipid emulsification and interaction with apolipoprotein B (apoB) to promote chylomicron assembly and secretion. Postprandially, ApoA-IV dissociates from chylomicrons into the lipoprotein-free plasma fraction, where it activates lecithin-cholesterol acyltransferase (LCAT) and enhances lipoprotein lipase (LPL) activity via apoC-II, critical for triglyceride-rich lipoprotein catabolism.
ApoA-IV exhibits protective roles against cardiovascular disease (CVD) by inhibiting vascular inflammation through NF-κB suppression and upregulating DHCR24, an anti-inflammatory enzyme. Genetic variants like APOA4 S347 correlate with elevated coronary heart disease (CHD) risk and reduced plasma ApoA-IV levels. In metabolic regulation, ApoA-IV improves insulin sensitivity by stimulating GLUT4 translocation in adipocytes via PI3K-Akt pathways and enhances glucose-stimulated insulin secretion, with deficiencies linked to glucose intolerance. Chronic high-fat diets blunt its satiety signaling, contributing to obesity, while Roux-en-Y gastric bypass increases ApoA-IV, correlating with weight loss and improved glucose control.
Clinically, ApoA-IV serves as a biomarker for CHD risk and diabetes progression. Therapeutic strategies targeting its anti-inflammatory, insulinotropic, and lipid-modulating properties show promise for metabolic and cardiovascular disorders.
Common uses include lipid metabolism studies.
Available while supplies last. Product will not be remanufactured. Please see the Product Change Notice.
Not a hazardous substance or mixture.
12 - Non Combustible Liquids